FDA Section 361 vs 351 Compliance for Biologic Suppliers

FDA Section 361 human cells, tissues, and cellular and tissue-based products (HCT/Ps) are regulated strictly as tissue products requiring minimal manipulation and homologous use, exempting them from premarket IND or BLA approval under 21 CFR Part 1271. In contrast, Section 351 products involve more-than-minimal manipulation, non-homologous intent, or systemic metabolic activity, classifying them as biological drugs subject to full FDA premarket review. Navigating FDA Section 361 vs 351 compliance for biologic suppliers is essential for medical practice managers and clinical directors to ensure regulatory compliance, patient safety, and operational continuity.

Regulatory Definitions: Section 361 vs. Section 351 HCT/Ps

The regulatory pathway governing human tissue products in the United States is established under the Public Health Service (PHS) Act and enforced through Title 21 of the Code of Federal Regulations (21 CFR Part 1271). Understanding the explicit boundaries between Section 361 tissue products and Section 351 biological drugs dictates how products must be manufactured, marketed, and administered within a clinical practice.

Criteria for Section 361 Qualification

To qualify as a Section 361 HCT/P, a tissue product must meet all four objective criteria set forth in 21 CFR 1271.10(a):

1. Minimal Manipulation: Processing does not alter the original relevant characteristics of structural tissue (e.g., reconstruction, buffering, or cushioning) or the biological characteristics of non-structural tissue.
2. Homologous Use Only: The tissue is intended to perform the same basic function in the recipient as it performed in the donor (e.g., providing structural support, fluid replacement, or barrier function).
3. No Combination With Other Articles: The product is not combined with another drug or device, except for water, crystalloids, or approved sterilizing, preserving, or storage agents that do not raise new safety concerns.
4. Systemic Effect and Cellular Dependence: The product either does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, or it is intended for autologous use, reproductive use, or first- or second-degree blood relatives.

Products meeting all four conditions do not require premarket approval, investigational drug clearance, or biological licensing. However, manufacturers must maintain active FDA registration, comply with Current Good Tissue Practice (cGTP), and report adverse events.

Defining Section 351 Biological Drugs

If a product fails to meet even one of the Section 361 criteria, it is categorized as a Section 351 biological drug. Section 351 products—including isolated cellular products that depend on metabolic activity, extracellular vesicles, or highly processed cell suspensions—require formal FDA oversight. This involves Investigational New Drug (IND) applications for clinical trials and Biologics License Applications (BLAs) before commercial marketing is permitted. Procuring Section 351 products that lack an approved BLA or active IND exposes practice operations to severe regulatory scrutiny.

Operational Procurement Checklist for Practice Administrators

Practice administrators bear the operational responsibility of auditing supply chains and ensuring that every tissue allograft brought into the facility adheres strictly to federal guidelines. Procuring unapproved biological drugs marketed improperly as Section 361 tissues creates significant legal exposure and potential operational disruption.

When evaluating biologics suppliers, practice managers should execute the following verification steps:

• Verify FDA Establishment Registration: Request the supplier's active FDA Form 3471 (Tissue Establishment Registration). Ensure the registration is active and lists the specific facility where the tissue is processed.
• Examine Processing Protocols: Obtain documentation verifying that processing methods meet minimal manipulation criteria. For structural tissues such as Wharton's jelly or umbilical cord tissue, confirm that structural integrity is preserved without chemical digestion or isolation of specific cellular subsets.
• Inspect Lot-Specific Certificates of Analysis (COAs): Confirm that every lot includes comprehensive safety testing documentation. This includes USP <71> sterility testing, endotoxin testing, and screening for communicable diseases (including HIV, Hepatitis B/C, Syphilis, and HTLV).
• Review Supplier Promotional Claims: Ensure the supplier does not market Section 361 products for non-homologous uses or claim systemically active drug-like mechanisms. Promotional materials alleging disease treatment or organ regeneration trigger Section 351 classification.
• Audit Cold-Chain Management: Confirm that the supplier provides validated temperature-controlled logistics, clear storage protocols (e.g., ambient, liquid nitrogen vapor phase, or ultra-low freezer requirements), and uncompromised chain-of-custody documentation.

Clinical Governance: Homologous Use Standards for Clinicians

While administrators handle supplier vetting, treating physicians retain clinical responsibility for ensuring that the administration of a tissue allograft aligns with the regulatory standard of homologous use. FDA guidelines emphasize that homologous use depends entirely on the intended clinical purpose of the tissue.

Structural Tissues in Practice

For structural tissue allografts derived from human umbilical cord, amnion, or connective tissue, homologous use means the tissue is applied to repair, reconstruct, replace, or supplement structural defects. For clinicians specializing in orthopedics, sports medicine, or pain management, utilizing structural allografts to provide a protective scaffold or barrier in focal connective tissue defects aligns with established homologous definitions.

Conversely, injecting structural allografts for systemic conditions, central nervous system disorders, or metabolic therapy falls outside homologous parameters. When a clinical protocol purports to achieve systemic biological therapeutic effects, the FDA views the procedure as administering an unapproved Section 351 drug. Clinicians working closely with regenerative medicine doctors must ensure clinical documentation reflects true structural and protective intent.

Financial and Liability Risks of Non-Compliant Procurement

Procuring products from non-compliant suppliers presents substantial risks to medical practice viability, insurance coverage, and professional licensure.

`` +-----------------------------------------------------------------------+ | REGULATORY NON-COMPLIANCE | +-----------------------------------+-----------------------------------+ | CLINICAL IMPACT | OPERATIONAL & FINANCIAL IMPACT | | - Patient safety risks | - FDA Warning Letters & Seizures | | - Unvalidated handling protocols | - Insurer Audits & Clawbacks | | - Adverse event liability | - Practice Reputational Damage | +-----------------------------------+-----------------------------------+ ``

Operational Risks

The FDA routinely issues Warning Letters and Untoward Event notices to tissue banks and distributors operating outside Section 361 parameters. If a supplier receives a warning letter or product recall, practices holding inventory may face immediate product confiscation, disruption of patient appointment schedules, and unexpected financial losses from unusable stock.

Malpractice and Liability Exposure

Medical malpractice insurance policies frequently exclude coverage for procedures utilizing unapproved experimental drugs or off-label biological products that lack FDA compliance. If an adverse event occurs following the administration of a product deemed an unapproved Section 351 drug, the practice and administering provider may face uninsured legal liabilities.

What This Means for Your Practice

To safeguard clinical operations and ensure regulatory alignment, practice leadership should immediately implement the following operational controls:

1. Conduct an Inventory Audit: Cross-reference all current tissue allografts, cell-derived liquids, and biologic products against vendor regulatory files to verify Section 361 eligibility.
2. Establish a Standardized Procurement SOP: Require written compliance review approval from the medical director and practice administrator before onboarding any new biologic vendor.
3. Standardize Patient Informed Consent: Ensure patient consent forms accurately reflect the structural and homologous nature of Section 361 tissue allografts without making unapproved therapeutic claims.
4. Review Vendor Documentation Annualy: Require suppliers to submit updated FDA registration status, cGTP audit summaries, and COA templates on an annual basis.

By establishing strict vendor qualification protocols, practices maintain high clinical standards while protecting their operational integrity. For additional detail regarding regulatory parameters and vendor screening standards, review our comprehensive compliance FAQ section.

Partnering for Compliant Biologic Procurement

Navigating regulatory requirements requires an experienced distribution partner committed to quality control, regulatory transparency, and clinical support. Learn more about our quality management protocols or request vendor documentation directly from our team to evaluate compliance for your practice.

To discuss your practice’s procurement requirements or request a compliance audit of your current biologic inventory, contact Dallas Regenerative Solutions today.